

Simone Barsotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4724480/publications.pdf>

Version: 2024-02-01

59
papers

1,168
citations

471061

17
h-index

414034

32
g-index

60
all docs

60
docs citations

60
times ranked

1374
citing authors

#	ARTICLE	IF	CITATIONS
1	The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. <i>Lancet Rheumatology</i> , The, 2020, 2, e71-e83.	2.2	182
2	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1144.	0.4	133
3	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	1.0	118
4	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 71-80.	2.9	60
5	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 253-257.	2.5	46
6	Thigh magnetic resonance imaging for the evaluation of disease activity in patients with idiopathic inflammatory myopathies followed in a single center. <i>Muscle and Nerve</i> , 2016, 54, 666-672.	1.0	38
7	Current Treatment for Myositis. <i>Current Treatment Options in Rheumatology</i> , 2018, 4, 299-315.	0.6	36
8	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. <i>Journal of Rheumatology</i> , 2019, 46, 279-284.	1.0	36
9	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , 2021, 60, 5028-5041.	0.9	34
10	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 44-49.	0.4	30
11	Cancer-associated myositis: a 35-year retrospective study of a monocentric cohort. <i>Rheumatology International</i> , 2014, 34, 565-569.	1.5	26
12	COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. <i>Lancet Rheumatology</i> , The, 2021, 3, e166-e168.	2.2	25
13	One year in review 2021: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 3-12.	0.4	25
14	Successful Treatment of Refractory Adult-Onset Still Disease With Canakinumab. <i>Journal of Clinical Rheumatology</i> , 2014, 20, 121.	0.5	24
15	Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. <i>Clinical and Experimental Medicine</i> , 2019, 19, 357-366.	1.9	23
16	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000784.	1.8	19
17	Performance of the new EULAR/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 492-497.	1.6	18
18	Risk factors for relapse and long-term outcome of idiopathic retroperitoneal fibrosis. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 1147-1153.	0.7	17

#	ARTICLE	IF	CITATIONS
19	One year in review 2019: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 3-14.	0.4	17
20	One year in review 2016: systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 569-74.	0.4	15
21	Myositis an evolving spectrum of disease. <i>Immunological Medicine</i> , 2018, 41, 46-54.	1.4	14
22	Is there a role for laser speckle contrast analysis (LASCA) in predicting the outcome of digital ulcers in patients with systemic sclerosis?. <i>Clinical Rheumatology</i> , 2020, 39, 69-75.	1.0	14
23	One year in review 2018: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 3-23.	0.4	14
24	Muscular vasculitis confined to lower limbs: description of two case reports and a review of the literature. <i>Rheumatology International</i> , 2017, 37, 2115-2121.	1.5	13
25	The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature. <i>Reumatismo</i> , 2018, 70, 78-84.	0.4	13
26	High sensitivity troponin might be a marker of subclinical scleroderma heart involvement: a preliminary study. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 183-187.	1.0	12
27	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. <i>Journal of Rheumatology</i> , 2022, 49, 176-185.	1.0	12
28	One year in review 2017: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 3-20.	0.4	11
29	One year in review 2018: idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 937-947.	0.4	11
30	One year in review 2020: idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1-12.	0.4	10
31	Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy). <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 90.	1.2	9
32	One year in review 2016: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 3-13.	0.4	9
33	Idiopathic inflammatory myopathies: one year in review 2021. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 199-209.	0.4	8
34	Clinically Amyopathic Dermatomyositis. <i>Journal of Clinical Neuromuscular Disease</i> , 2014, 15, 157-160.	0.3	7
35	Systemic sclerosis: a critical digest of the recent literature. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S3-14.	0.4	7
36	One year in review 2019: idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1-10.	0.4	7

#	ARTICLE	IF	CITATIONS
37	Drugs in induction and treatment of idiopathic inflammatory myopathies. <i>Autoimmunity Highlights</i> , 2014, 5, 95-100.	3.9	6
38	<p>Management of digital ulcers in systemic sclerosis</p>. <i>Chronic Wound Care Management and Research</i> , 0, Volume 6, 9-18.	0.4	6
39	Real life picture of the use of intravenous immunoglobulins in idiopathic inflammatory myopathies: Results of a multicentric study. <i>Autoimmunity Reviews</i> , 2021, 20, 102757.	2.5	6
40	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 240-250.	2.9	6
41	One year in review 2016: idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 966-974.	0.4	6
42	One year in review 2020: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 3-17.	0.4	6
43	Systemic vasculitis and the lung. <i>Current Opinion in Rheumatology</i> , 2017, 29, 45-50.	2.0	5
44	Bioelectrical Impedance Vector Analysis for Nutritional Status Assessment in Systemic Sclerosis and Association With Disease Characteristics. <i>Journal of Rheumatology</i> , 2021, 48, 728-734.	1.0	5
45	One year in review 2017: idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 875-884.	0.4	5
46	Systemic sclerosis chronic ulcers: preliminary results of treatment with allogenic skin grafting in a cohort of Italian patients. <i>International Wound Journal</i> , 2016, 13, 1050-1051.	1.3	4
47	Assessment of swallowing function with oroâ€pharyngealâ€esophageal scintigraphy in patients with idiopathic inflammatory myopathies. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13599.	1.6	4
48	The impact of skin calcinosis on digital ulcers in patients with SSc : clinical and prognostic stratification using the â€œwound bed scoreâ€€. <i>International Wound Journal</i> , 2020, 17, 1783-1790.	1.3	4
49	One year in review 2020: idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1-12.	0.4	4
50	Histopathology of the muscle in rheumatic diseases. <i>Reumatismo</i> , 2018, 70, 133-145.	0.4	3
51	Cardiovascular burden in systemic sclerosis: QRISK3 versus Framingham for risk estimation. <i>Modern Rheumatology</i> , 2022, 32, 584-588.	0.9	2
52	One year in review 2015: idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 593-601.	0.4	1
53	One year in review 2021: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 3-12.	0.4	1
54	Evaluation of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies Through Semiquantitative and Quantitative Analysis of Lung Computed Tomography. <i>Journal of Thoracic Imaging</i> , 2022, 37, 344-351.	0.8	1

#	ARTICLE	IF	CITATIONS
55	FP078LONG-TERM EFFECTS AND OUTCOME OF IDIOPATHIC RETROPERITONEAL FIBROSIS MANAGEMENT. Nephrology Dialysis Transplantation, 2018, 33, i74-i75.	0.4	0
56	SAT0290â€¦TRADITIONAL AND DISEASE-RELATED RISK FACTORS FOR ARTERIAL AND VENOUS THROMBOTIC EVENTS (TE) IN IDIOPATHIC INFLAMMATORY MYOPATHIES (IIM). , 2019, , .		0
57	SAT0260â€¦MUSCULAR INVOLVEMENT OF THE LOWER LIMBS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A MRI EVALUATION. , 2019, , .		0
58	Cardiometabolic risk and subclinical vascular damage assessment in idiopathic inflammatory myopathies: a challenge for the clinician. Clinical and Experimental Rheumatology, 2019, 37, 1036-1043.	0.4	0
59	One year in review 2021: idiopathic inflammatory myopathies.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0